Global Information
회사소개 | 문의 | 비교리스트

세계의 화학요법 유발성 오심 구토(CINV) 치료제 시장(2017-2021년)

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 12월 상품 코드 421631
페이지 정보 영문 77 Pages
가격
US $ 2,500 ₩ 3,021,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,625,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,043,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 화학요법 유발성 오심 구토(CINV) 치료제 시장(2017-2021년) Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021
발행일 : 2016년 12월 페이지 정보 : 영문 77 Pages

세계의 화학요법 유발성 오심 구토(CINV) 치료제 시장은 2017-2021년 연평균 성장률(CAGR) 5.41%로 성장할 전망입니다.

세계의 화학요법 유발성 오심 구토(CINV) 치료제(Chemotherapy-induced Nausea and Vomiting Drugs) 시장에 대해 조사했으며, 시장 동향과 과제, 치료별 및 지역별 동향, 2021년까지 시장 성장 전망, 주요 벤더 개요 등의 정보를 전해드립니다.

제1장 주요 요약

제2장 조사 범위

제3장 시장 조사 방법

제4장 서론

제5장 질환 개요

  • 질환의 이해
  • 병태생리학
  • 중앙 경로
  • 말초 경로
  • 질환 관리

제6장 파이프라인 분석

제7장 시장 상황

  • 시장 개요
  • Five Forces 분석

제8장 치료별 시장 세분화

  • 세라토닌 수용체 길항제
  • NK1 수용체 길항제
  • 기타

제9장 지역별 세분화

  • 아메리카
  • 유럽, 중동 및 아프리카
  • 아시아태평양 지역

제10장 시장 성장 촉진요인

  • 암 인구 증가가 시장 성장을 촉진
  • 개발도상국의 화학요법 치료제 도입 확대
  • 신약 인가가 시장 성장을 가속

제11장 성장 촉진요인의 영향

제12장 시장이 해결해야 할 과제

  • 선진국에서 암의 대체적 치료 인기
  • 특허에 의한 독점성 상실이 제네릭과의 경쟁을 격화
  • 기존 치료제의 한계가 성장 전망을 저해

제13장 성장 촉진요인과 해결해야 할 과제의 영향

제14장 시장 동향

제15장 벤더 구도

  • 경쟁 시나리오

제16장 주요 벤더 분석

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck
  • Tesaro
  • 기타 주목해야 할 벤더

제17장 부록

제18장 Technavio 소개

도표

KSM 17.01.31

About CINV Drugs

The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.

Technavio's analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck
  • Tesaro

Other Prominent Vendors

  • Acacia Pharma
  • Aphios
  • Baxter Healthcare
  • Dr. Reddy's Laboratories
  • Eisai
  • Especificos Stendhal
  • F. Hoffmann-La Roche
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical Holdings
  • Midatech Pharma
  • Mundipharma
  • Mylan
  • Ono Pharmaceutical
  • OPKO Health
  • Orchid Chemicals & Pharmaceuticals
  • Otsuka Pharmaceutical
  • Purdue Pharma
  • Sandoz (a subsidiary of Novartis)
  • SciClone Pharmaceuticals
  • Shin Nippon Biomedical Laboratories
  • Solasia Pharma K.K.
  • Specialised Therapeutics
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals

Market driver

  • Growing preference of chemotherapy drugs in developing countries
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of alternate therapies for the treatment of cancer in developed countries
  • For a full, detailed list, view our report

Market trend

  • Increasing inorganic growth strategies likely to fuel the market growth
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Highlights

PART 05: Disease overview

  • Understanding the disease
  • Pathophysiology
  • Central pathway
  • Peripheral pathway
  • Management of disease

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global CINV drugs market
  • Five forces analysis

PART 08: Market segmentation by therapy

  • Serotonin receptor antagonists
  • NK1 receptor antoagonists
  • Others

PART 09: Geographical segmentation

  • CINV drugs market in Americas
  • CINV drugs market in EMEA
  • CINV drugs market in APAC

PART 10: Market drivers

  • Growing cancer population driving the market growth
  • Growing preference for chemotherapy drugs in developing countries
  • Approval of new drugs fuels the market growth

PART 11: Impact of drivers

PART 12: Market challenges

  • Growing popularity of alternate therapies for the treatment of cancer in developed countries
  • Loss of patent exclusivities increasing generic competition
  • Limitations in existing therapies hindering the growth prospects

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Robust R&D activities fueling the pipeline
  • Increasing inorganic growth strategies likely to fuel the market growth
  • Novel treatment options coupled with new applications

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck
  • Tesaro
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Pipeline landscape
  • Exhibit 03: Key pipeline candidates
  • Exhibit 04: Global CINV drugs market snapshot
  • Exhibit 05: Analysis of global CINV drugs market
  • Exhibit 06: Global CINV drugs market 2016-2021 ($ billions)
  • Exhibit 07: Key initiatives in emerging economies
  • Exhibit 08: Opportunity analysis of global CINV drugs market
  • Exhibit 09: Opportunity analysis in developed and emerging markets
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Segmentation of global CINV drugs market by therapy 2016 (% share)
  • Exhibit 12: Lifecycle analysis of segments in global CINV drugs market
  • Exhibit 13: Geographic segmentation by revenue 2016 and 2021
  • Exhibit 14: Geographic segmentation by revenue 2016 ($ millions)
  • Exhibit 15: Market scenario in Americas
  • Exhibit 16: CINV drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 17: Market scenario in EMEA
  • Exhibit 18: CINV drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in APAC
  • Exhibit 20: CINV drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 21: Key drivers and challenges in APAC
  • Exhibit 22: Top ten cancers in the US in 2013
  • Exhibit 23: Key approvals in the market in 2015 and 2016
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
  • Exhibit 26: Forcefield analysis of drivers and challenges
  • Exhibit 27: Impact of drivers and challenges
  • Exhibit 28: Key vendors that are extensively conducting R&D activities
  • Exhibit 29: Competitive structure analysis of global CINV drugs market 2015
  • Exhibit 30: Market share analysis in global CINV drugs market
  • Exhibit 31: Competitive analysis of global CINV drugs market
  • Exhibit 32: Market penetration of various global CINV drugs manufacturers 2015
  • Exhibit 33: GlaxoSmithKline: Strength assessment
  • Exhibit 34: GlaxoSmithKline: Strategy assessment
  • Exhibit 35: GlaxoSmithKline: Opportunity assessment
  • Exhibit 36: Helsinn: Key highlights
  • Exhibit 37: Helsinn: Strength assessment
  • Exhibit 38: Helsinn: Strategy assessment
  • Exhibit 39: Helsinn: Opportunity assessment
  • Exhibit 40: Heron Therapeutics: Key highlights
  • Exhibit 41: Heron Therapeutics: Strength assessment
  • Exhibit 42: Heron Therapeutics strategy assessment
  • Exhibit 43: Heron Therapeutics: Opportunity assessment
  • Exhibit 44: Merck: Key highlights
  • Exhibit 45: Merck: strength assessment
  • Exhibit 46: Merck: Strategy assessment
  • Exhibit 47: Merck: Opportunity assessment
  • Exhibit 48: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions)
  • Exhibit 49: Tesaro: Key highlights
  • Exhibit 50: Tesaro: Strength assessment
  • Exhibit 51: Tesaro: Strategy assessment
  • Exhibit 52: Tesaro: Opportunity assessment
Back to Top
전화 문의
F A Q